These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 6489413)

  • 21. Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia.
    Raslová K; Dubovská D; Mongiellová V; Trnovec T
    Eur J Clin Pharmacol; 1997; 52(2):101-6. PubMed ID: 9174678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia.
    Packard CJ; Stewart JM; Third JL; Morgan HG; Lawrie TD; Shepherd J
    Biochim Biophys Acta; 1980 Apr; 618(1):53-62. PubMed ID: 6990991
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.
    Tesone PA; Gladstein J; Acuña AM
    Curr Med Res Opin; 1985; 9(9):650-7. PubMed ID: 3902379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia.
    Malmendier CL; Delcroix C
    Atherosclerosis; 1985 May; 55(2):161-9. PubMed ID: 3924068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
    Leiss O; Meyer-Krahmer K; von Bergmann K
    J Lipid Res; 1986 Jul; 27(7):713-23. PubMed ID: 3760707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients.
    Sirtori CR; Montanari G; Gianfranceschi G; Sirtori M; Galli G; Bosisio E
    Eur J Clin Pharmacol; 1985; 28(6):619-24. PubMed ID: 3840743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
    Sznajderman M
    Pol Arch Med Wewn; 1980 Jun; 63(6):543-9. PubMed ID: 7402954
    [No Abstract]   [Full Text] [Related]  

  • 29. [Quantitative analysis of lipoproteins in hyperlipoproteinemias of type IIa, IIb and IV (author's transl)].
    Loeper J; Goy-Loeper J; Rouffy J
    Clin Chim Acta; 1979 Oct; 98(1-2):19-26. PubMed ID: 227624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Levels of tumor necrosis factor alpha in serum of patients with hyperlipoproteinemia IIB before and after micronized fenofibrate therapy].
    Madej A; Okopień B; Kowalski J; Zieliński M; Wysocki J; Szyguła B; Kalina Z; Herman Z
    Pol Arch Med Wewn; 1998 Apr; 99(4):308-13. PubMed ID: 9760818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Cheung J; Crook MA
    QJM; 1997 Oct; 90(10):631-4. PubMed ID: 9415344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
    Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L; Németh Csóka M; Szám I; Pados G; Karádi I; Köszegi G; Kusztos R
    Orv Hetil; 1986 Oct; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract]   [Full Text] [Related]  

  • 36. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.
    Simons LA; Hickie JB; Balasubramaniam S
    Atherosclerosis; 1985 Jan; 54(1):75-88. PubMed ID: 3888229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
    Paragh G; Seres I; Harangi M; Balogh Z; Illyés L; Boda J; Szilvássy Z; Kovács P
    Diabetes Metab; 2003 Dec; 29(6):613-8. PubMed ID: 14707891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
    Smud R; Sermukslis B
    Curr Med Res Opin; 1987; 10(9):612-24. PubMed ID: 3436157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.